Bumper Offer - Urjas oil Just @ Rs. 1
Montair 5 Tablet (15), a prescription drug, is manufactured in various forms such as Tablet. It is typically used for the treatment of Asthma, Allergic Rhinitis. The alternative uses of Montair 5 Tablet (15) have also been explained below.
Medical history of the patient along with age and gender determines the dosage of Montair 5 Tablet (15). Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Refer to the dosage section for a detailed discussion.
Some other side effects of Montair 5 Tablet (15) have been listed ahead. These side effects of Montair 5 Tablet (15) are usually temporary and subside with the completion of treatment. However, if these continue for a longer time, consult your doctor right away.
It is also important to note that Montair 5 Tablet (15) has a Moderate effect for pregnant women and Moderate effect on lactating mothers. Warnings related to Montair 5 Tablet (15)'s effects on the liver, heart and kidney, if any, have been listed below.
Some other conditions that can be affected by Montair 5 Tablet (15) are listed in the contraindications section below.
Drug reaction of Montair 5 Tablet (15) with other medicines has been reported. See below for a complete list.
You should also be aware that Montair 5 Tablet (15) is safe while driving, and is addiction.
Montair 5 Tablet (15) is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
| 13 - 18 years (Adolescent) |
|
| 2 - 12 years (Child) |
|
Based on research, the following side effects have been observed when Montair 5 Tablet (15) is used -
Severe
Moderate
Mild
Is the use of Montair 5 Tablet (15) safe for pregnant women?
Montair may cause moderate side effects during pregnancy. If you feel its harmful effects, then stop taking this drug immediately, and do not take Montair again without your doctor's advice.
Is the use of Montair 5 Tablet (15) safe during breastfeeding?
Breastfeeding women may feel side effects of Montair. If you see any side effects, stop taking Montair immediately and talk to your doctor. Take Montair again, only after your doctor's advice.
What is the effect of Montair 5 Tablet (15) on the Kidneys?
Montair has very mild side effects on the kidneys.
What is the effect of Montair 5 Tablet (15) on the Liver?
Montair can have moderate side effects on the liver. If you notice any harmful effects then stop taking this drug right away. Consult your doctor before using this medicine again.
What is the effect of Montair 5 Tablet (15) on the Heart?
Montair is rarely harmful for the heart.
Montair 5 Tablet (15) should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Montair 5 Tablet (15) unless your doctor advises you to do so -
Is this Montair 5 Tablet (15) habit forming or addictive?
No, there is no any evidence that Montair 5 Tablet (15) is addictive.
Is it safe to drive or operate heavy machinery when consuming?
Montair 5 Tablet (15) does not cause dizziness or sleep, so you can drive a vehicle or operate machinery also.
Is it safe?
Montair 5 Tablet (15) should be used only after doctor's advice.
Is it able to treat mental disorders?
No, the use of Montair 5 Tablet (15) in mental disorders is not effective.
Interaction between Food and Montair 5 Tablet (15)
There is no information on the effects of taking Montair 5 Tablet (15) with food, because this topic has not been scientifically researched yet.
Interaction between Alcohol and Montair 5 Tablet (15)
Consult your doctor before consuming alcohol while taking Montair 5 Tablet (15) as it can have severe side effects.
This medicine data has been created by -
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 873-874
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 228
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Singulair® (montelukast sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Lukair® (montelukast sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 873-874
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 228
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Singulair® (montelukast sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Lukair® (montelukast sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 873-874
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 228
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Singulair® (montelukast sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Lukair® (montelukast sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 873-874
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 228
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Singulair® (montelukast sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Lukair® (montelukast sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 873-874
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 228
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Singulair® (montelukast sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Lukair® (montelukast sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 873-874
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 228
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Singulair® (montelukast sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Lukair® (montelukast sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 873-874
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 228
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Singulair® (montelukast sodium)
Therapeutic Goods Administration (TGA): Department of Health [Internet]. Governmet of Australia; Package leaflet information for the user; Lukair® (montelukast sodium)
